Safety and Efficacy of Dexmedetomidate vs. Midazolam for Procedural Sedation During Medical Thoracoscopy

Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age12-90
SponsorPost Graduate Institute of Medical Education and Research, Chandigarh

About this trial

Medical thoracoscopy can be performed under procedural sedation (conscious sedation) in most of the cases. Procedural sedation is a state where the patient lies comfortably without much movement, does not feel pain and has a dissociative state (separation of mind and body. In view of the existing literature, we hypothesize that use of dexmedetomidine for procedural sedation during medical thoracoscopy will improve the ease of performing the procedure, lower the consumption of rescue analgesics and risk of intra- and post-procedure complications, improve the yield, shorten the recovery period and reduce the post-procedure pain in comparison to midazolam. In this study we propose to show that procedural sedation with dexmedetomidine during medical thoracoscopy is more beneficial for both patient and the clinician in terms of yield and shorter procedure time in comparison with conventional midazolam-fentanyl combination.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age≥18 and ≤80 years

Medical thoracoscopy performed for the work-up of undiagnosed pleural effusion

Disqualifiers

Patients with ICD in situ for more than 5 days

SP02<92%

Haemodynamic instability (systolic blood pressure ≤90 mmHg or >180mmHg, or diastolic BP >110mmHg) before the procedure

MI/unstable angina in the last 3 months

Trial design

Design model

Parallel

Treatments tested in this trial

  • Dexmedetomidine

    Drug

    The patient will receive dexmedetomidine bolus dose of 1 µg /Kg over 10 minutes followed by 0.5 µg /kg/hr infusion titrated to desired sedation level (RSS 3). For patients who do not achieve an RSS of 3, we will give 1 mg bolus of midazolam. All additional boluses will be recorded. The patient will initially receive a bolus of 2 mL 0.9% normal saline intravenously for blinding purpose

  • Midazolam

    Drug

    The patient will receive midazolam bolus dose of 2 mg IV. They will receive an infusion of normal saline over 10 minutes for blinding purpose. Further need of sedation (as assessed by RSS) will be met by additional IV boluses of 1 mg midazolam. During the procedure they will receive continuous infusion of normal saline at a rate of 0.5 µg /Kg/Hr as placebo.

Treatment groups

56 Participants
are divided into 2 treatment groups
Group A: Group 1Experimental treatment 1 intervention
Group B: Group 2Active comparator 1 intervention

Trial outcomes

Primary outcomes

1

Total amount of rescue medication (sedation or analgesia) required during MT.

The total amount of rescue medication bolus will be counted

Time frame
6 hours

Secondary outcomes

1

Pulmonologist rated ease of the procedure (satisfaction visual analogue scale [VAS])

Operator rated ease of procedure will be analysed using VAS (0 mm being very easy; 100 being most difficult)

Time frame
6 hours
2

Pulmonologist rated incidence of cough on 100 mm VAS (cough VAS);

Operator s assessment of cough during procedure will be assessed using VAS

Time frame
6 hours
3

Patient rated VAS 2 hours after completion of the procedure

Patients comfort during procedure will be assessed after procedure using VAS (0 mm being very comfortable; 100 mm being very uncomfortable)

Time frame
6 hours
4

Willingness to undergo repeat thoracoscopy if required

Patient's willingness to undergo procedure will be assessed using visual analogue scale (0 mm being least willing; 100 being most willing)

Time frame
6 hours

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.